BIO Trinity21 Jun 2021 09:09
Sareum to Present at BioTrinity 2021 Conference
Cambridge, UK, 21 June 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that its CEO, Dr Tim Mitchell, will give a company presentation at 10:30am BST today at the BioTrinity 2021 conference.
In his presentation, Dr Mitchell will showcase Sareum's two proprietary TYK2/JAK1 kinase inhibitor programmes: SDC-1801 targeting autoimmune diseases and the severe inflammatory responses and respiratory symptoms arising from Covid-19 and other viral infections, and SDC-1802 targeting cancers.
The presentation is available to delegates of BioTrinity 2021, and a copy of the slides will be made publicly available on Sareum's website after the presentation - www.sareum.com.